Our expert faculty will provide you with senior executive-level expert insight on all of your critical success factors:
- - An up-to-date toolkit for regulatory submission packages that will guarantee timely approval, including the latest insights on the FDA’s draft guidelines for biosimilars
- - Success strategies from industry leaders on how to overcome IP challenges and guarantee product availability
- - An unequaled spectrum of international case studies offering lessons on the commercialization of biosimilars and generic drugs in North and South America, Western and Eastern Europe, North Africa, the Middle East, and the Far East
Featured Session on FDA Regulatory Updates:
- - Outlook and Strategic Impact of U.S. Biosimilar Approval Pathway from Pfizer and Shire
- - Regulatory Extrapolation of Therapeutic Indications for Complex Biosimilars: Clinical and Regulatory Updates, and Ways to Proceed from Takeda Pharmaceuticals
- - Think Different: Navigating the Brave New Globalized Life Sciences Industry presented by G. Steven Burrill, CEO, BURRILL & COMPANY
- - Reimbursement Strategies for Generics & Biosimilars Around the World presented by Express Scripts and Bristol Myers Squibb
The 13th Annual Business of Biosimilars and Generic Drugs will take place September 10-12, 2012 in Boston, MA. As a reader of this blog, you receive an exclusive discount of 25% off of the standard price when you register to join us and use priority code XP1786BLOG. Have any questions about the event? Feel free to email Jennifer Pereira. or visit the webpage: http://bit.ly/Ja99wS
Share this article with your social network, just click below to share now!
|
|
No comments :
Post a Comment